Research and Development Project Manager at NanoMedSyn - Montpellier, Occitanie, France
NanoMedSyn develops new targeted therapeutics to treat Lysosomal Storage Disorders. Thanks to proprietary synthetic derivatives (named AMFA), NanoMedSyn provides a compound with an high affinity for the mannose 6-phosphate receptor, responsible for the targeting of enzymes to the lysosome. A new generation of enzymes for the therapy of Lysosomal Diseases is now possible.